Most life sciences transactions result in intellectual property (IP) due diligence being carried out on underlying IP assets that are often central to the transaction. Typically, this includes a focus ...
As companies and markets increasingly view patents not just as a defensive shield but as strategic assets (e.g., for licensing, enforcement, or other potential revenue generation), the prosecution ...
The USPTO is in the midst of a meaningful reset—one that is reshaping how patent applications are examined, how discretion is exercised, and how prosecution outcomes are ultimately determined. Shifts ...
September 29, 2025 - Life sciences transactions necessarily result in intellectual property (IP) due diligence being carried out on the underlying IP assets that are often a central part of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results